Selecta Biosciences (NASDAQ:SELB)‘s stock had its “buy” rating reaffirmed by Stifel Nicolaus in a report issued on Friday, AnalystRatings.com reports. They presently have a $6.00 target price on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 331.65% from the company’s previous close.
Several other analysts also recently commented on SELB. Zacks Investment Research downgraded shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, October 10th. ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Mizuho reaffirmed a “buy” rating and set a $4.00 price objective on shares of Selecta Biosciences in a report on Sunday, August 11th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $6.67.
SELB stock traded down $0.15 during trading hours on Friday, hitting $1.39. The company’s stock had a trading volume of 15,694 shares, compared to its average volume of 161,167. The company has a market capitalization of $70.76 million, a PE ratio of -0.48 and a beta of 1.11. Selecta Biosciences has a 12 month low of $1.28 and a 12 month high of $6.33. The stock has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $1.88.
Selecta Biosciences (NASDAQ:SELB) last posted its earnings results on Thursday, August 8th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.07). The business had revenue of $0.01 million for the quarter. On average, analysts predict that Selecta Biosciences will post -1.2 earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Polaris Venture Management Co. V L.L.C. acquired a new position in Selecta Biosciences during the 2nd quarter valued at $26,919,000. Monashee Investment Management LLC acquired a new position in Selecta Biosciences during the 2nd quarter valued at $350,000. JPMorgan Chase & Co. acquired a new position in Selecta Biosciences during the 2nd quarter valued at $4,215,000. Sphera Funds Management LTD. acquired a new position in Selecta Biosciences during the 3rd quarter valued at $3,989,000. Finally, Baker BROS. Advisors LP acquired a new position in Selecta Biosciences during the 3rd quarter valued at $2,550,000. 46.44% of the stock is owned by institutional investors and hedge funds.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
See Also: What is a SEC Filing?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.